[July 29, 2016]

SHAREHOLDER ALERT: Rosen Law Firm Reminds Emergent BioSolutions, Inc. Investors of Important Deadline in Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Emergent BioSolutions, Inc. common stock (NYSE:EBS) from January 11, 2016 through June 21, 2016, both dates inclusive (the "Class Period") of the important September 19, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Emergent BioSolutions investors under the federal securities laws.

To join the Emergent BioSolutions class action, go to the firm's website at http://rosenlegal.com/cases-922.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class ation.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants issued false and misleading statements relating to future lucrative contract renewals and demand from the U.S. government for its anthrax vaccine BioThrax. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 19, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm's website at http://rosenlegal.com/cases-922.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160729005809/en/

[ Back To TMCnet.com's Homepage ]